Table 1 Clinical features of 979 patients with MCL according to POD24 status.
From: POD24-Based prognostic signature enables personalized risk stratification in mantle cell lymphoma
Features | POD24 (n = 369) | Non-POD24(n = 610) | P- value |
|---|---|---|---|
Age(y) | 0.066 | ||
≥ 60 | 202 | 297 | |
< 60 | 167 | 313 | |
Sex | 0.823 | ||
Male | 283 | 464 | |
Female | 86 | 146 | |
B symptom | 0.003 | ||
Yes | 132 | 167 | |
No | 225 | 433 | |
LDH | 0.000 | ||
Elevated | 164 | 166 | |
Normal | 188 | 428 | |
ECOG | 0.005 | ||
>=2 | 276 | 73 | |
< 2 | 66 | 511 | |
Extranodal sites | 0.171 | ||
≥ 2 | 66 | 89 | |
<2 | 303 | 521 | |
HBsAg | 0.96 | ||
Positive | 38 | 62 | |
Negative | 311 | 513 | |
Ann Abor Stage | 0.076 | ||
I or II | 32 | 76 | |
III or IV | 329 | 528 | |
MIPI scores | 0.000 | ||
≥ 6 | 110 | 103 | |
<6 | 218 | 482 | |
Splenomegaly | 0.000 | ||
Yes | 193 | 249 | |
No | 163 | 349 | |
Ki67 | 0.000 | ||
<=30% | 291 | 112 | |
> 30% | 212 | 162 | |
NA | 107 | 95 | |
Anti-CD20 with induction | 0.000 | ||
Yes | 460 | 229 | |
No | 99 | 120 | |
Novel agent with induction | 0.042 | ||
Yes | 127 | 57 | |
No | 472 | 301 | |
Post-induction rituximab maintenance | 0.000 | ||
Yes | 179 | 56 | |
No | 421 | 306 | |
ASCT | 0.037 | ||
Yes | 68 | 26 | |
No | 540 | 340 |
